Vital Signs: How Medtech Companies Can Heal the Aches and Pains of Modern Healthcare Systems

Posted by Will Randall on November 15, 2018

Hospital spending has grown 15% and patient admissions are up 20% since 2009. Despite some efficiency gains, the provider financial deficit is large and growing, and patients are waiting longer than ever before for treatment in a system stretched to capacity. Sound familiar?


>
Read More

What Do IDNs Care About? We Have the Data

Posted by Joe Stevens on July 19, 2018

Paul Darling co-authored this blog post with Joe Stevens.

Physicians continue to trade in the keys to their private practices in exchange for employee badges within large provider systems. Integrated delivery networks have become major players in healthcare delivery, and pharmaceutical and medical device companies are working hard to tailor their commercial approaches to suit these increasingly complex and diverse stakeholders, which is proving to be quite the challenge. As one industry executive recently told me, “If you know one IDN, you know one IDN.”


>
Read More

The IDN Partnership Manifesto

Posted by Yuta Ito on June 21, 2018

Jonathan Freaney co-wrote this blog post with Yuta Ito. 

“Nothing happens until the pain of staying the same outweighs the pain of change.” 

The CEO of Atrium Health, Eugene Woods, opened the 2018 Healthcare Transformation Summit, held June 7-8 in Austin, Texas, with this quote along with examples of the transformation initiatives that Atrium was undertaking. While change is happening at a different pace across the U.S. and taking form in many ways, there was an air of consensus that partnership and collaboration with suppliers outside of their traditional “swim lanes” will hold the key to a successful and agile transformation. At the conference, we learned how these partnerships are taking shape and making a remarkable impact on the health systems and the patients they serve.


>
Read More

From Collision to Collaboration: How Diagnostics, Pharma and Patients Can Succeed Together

Posted by Jim Adelizzi on August 31, 2017

Pavan Anne co-wrote this blog post with Jim Adelizzi.

In this new era of personalized medicine, matching the right patient with the right targeted therapy requires pharmaceutical and diagnostic companies to reach across industry lines and collaborate long before launch. Together, they need to create a strategy that enables the companion diagnostic to differentiate and accelerate the therapy rather than impede its growth. I’ve witnessed a few ways that these entities can create a go-to-market strategy in unison and carry that tight-knit collaboration all the way to market. To illustrate the inherent challenges, let’s consider the case of two fictional oncology companies that have entered into a research and commercialization agreement: Pharma Depot Co. and Diagnostics “R” Us Inc. 


>
Read More